{"slideshow_credits": null, "snippet": "Pharmaceutical executives can look at the federal indictment and say that Martin Shkreli is an aberration, a rotten apple, but his arrest is not likely to make concern about drug prices go away.", "abstract": "News Analysis; arrest of Turing Pharmaceuticals chief executive Martin Shkreli on securities fraud charges in some ways has taken heat off of other drug firms; most of them will redouble efforts to distance themselves from greedy executive, who is blamed for sparking outrage over drug prices.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/12/18/business/martin-shkreli-arrest-gives-drug-makers-cover.html", "lead_paragraph": "Pharmaceutical executives can look at the federal indictment and say that Martin Shkreli is an aberration, a rotten apple, but his arrest is not likely to make concern about drug prices go away.", "headline": {"print_headline": "An Executive&#8217;s Arrest Gives Drug Makers Cover", "main": "Martin Shkreli\u2019s Arrest Gives Drug Makers Cover", "content_kicker": "News Analysis", "kicker": "News Analysis"}, "_id": "5673681738f0d85bed90f484", "word_count": "1341", "multimedia": [{"height": 126, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg", "legacy": {"thumbnail": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Securities and Commodities Violations", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Hedge Funds", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "An Analysis; News Analysis"}